Mark E. Davis | |
---|---|
Born | October 14, 1955 [1] |
Nationality | American |
Alma mater | University of Kentucky |
Known for | Molecular sieves, Drug delivery |
Awards | Princess of Asturias Award (2014) E. V. Murphree Award (2005) |
Scientific career | |
Fields | Chemical Engineering |
Institutions | California Institute of Technology |
Doctoral advisor | John Yamanis |
Mark E. Davis is the Warren and Katherine Schlinger Professor of Chemical Engineering at the California Institute of Technology. He is a member of the City of Hope National Medical Center. He earned his B.S., M.S., and Ph.D. in chemical engineering all from the University of Kentucky. His lab focuses on the synthesis of materials for catalysis and biocompatible materials for drug delivery. [2]
Davis was elected as a member into the National Academy of Engineering in 1997, for pioneering work in the synthesis of new catalytic materials.
He did his doctoral work with John Yamanis on reactions engineering with annular bed reactors. His academic career started as an assistant professor at Virginia Polytechnic Institute & State University in 1981 and rose until becoming the Charles O. Gordon Professor of Chemical engineering in 1990. During his time at Virginia Tech, he developed some of the earlier Zeolite molecular sieves and increasing the pore size. [3] [4] In 1991, he joined the faculty of the California Institute of Technology and served as the Executive Officer of the department from 1999 to 2004. In 2004 he joined the City of Hope National Medical Center, Comprehensive Cancer Center. [5]
In 1995, his wife, Mary, was diagnosed with breast cancer and had to go through chemotherapy. Having seen the side effects of cancer treatment, he decided to do research on molecules that would prevent drug from leaking through healthy blood vessels but would stop at the tumor. His group conjugated cyclodextrin to the anti-cancer compound camptothecin to improve the bio-availability and exhibit efficacy in mouse tumor models. [6] The compound, CRLX101 is now being tested in clinical trials. [7] The cyclodextrin nanoparticles are also being used to encapsulate siRNA.
He was the recipient of the Alan T. Waterman Award in 1990. In 1997, he was elected to the National Academy of Engineering, in 2006, to the National Academy of Sciences, and in 2011, the National Academy of Medicine. [8] He is also the founder of Insert Therapeutics and Calando Pharmaceuticals.
Mark was born in Ellwood City, Pennsylvania, as the son of teachers of history and English. [5] Mark Davis is an accomplished athlete and was on a full scholarship in track and field at the University of Kentucky. He is the 400-Meter World Champion for the 55–59 division. He was also part of the USA 4x100 and 4x400 meter teams. [9] He met his wife Mary while a professor at Virginia Tech. [7] She was an accomplished flautist before being diagnosed with breast cancer. [5]
Paul Hugh Emmett was an American chemist best known for his pioneering work in the field of catalysis and for his work on the Manhattan Project during World War II. He spearheaded the research to separate isotopes of uranium and to develop a corrosive uranium gas. Emmett also made significant contributions to BET Theory which explains the relationship between surface area and gas adsorption. He served on the faculty of Johns Hopkins University for 23 years throughout his scientific career.
Alexander J. Varshavsky is a Russian-American biochemist and geneticist. He works at the California Institute of Technology (Caltech) as the Morgan Professor of Biology. Varshavsky left Russia in 1977, emigrating to United States.
Rakesh K. Jain is the Andrew Werk Cook Professor of Tumor Biology at Massachusetts General Hospital in the Harvard Medical School and director of the E.L. Steele Laboratories for Tumor Biology at the Massachusetts General Hospital.
Myron Lee Bender (1924–1988) was born in St. Louis, Missouri. He obtained his B.S. (1944) and his Ph.D. (1948) from Purdue University. The latter was under the direction of Henry B. Hass. After postdoctoral research under Paul D. Barlett, and Frank H. Westheimer, he spent one year as a faculty member at the University of Connecticut. Thereafter, he was a professor of Chemistry at Illinois Institute of Technology in 1951, and then at Northwestern University in 1960. He worked primarily in the study of reaction mechanisms and the biochemistry of enzyme action. Myron L. Bender demonstrated the two-step mechanism of catalysis for serine proteases, nucleophilic catalysis in ester hydrolysis and intramolecular catalysis in water. He also showed that cyclodextrin can be used to investigate catalysis of organic reactions within the scope of host–guest chemistry. Finally, he and others reported on the synthesis of an organic compound as a model of an acylchymotrypsin intermediate.
Peter B. Dervan is the Bren Professor of Chemistry at the California Institute of Technology. The primary focus of his research is the development and study of small organic molecules that can sequence-specifically recognize DNA, a field in which he is an internationally recognized authority. The most important of these small molecules are pyrrole–imidazole polyamides. Dervan is credited with influencing "the course of research in organic chemistry through his studies at the interface of chemistry and biology" as a result of his work on "the chemical principles involved in sequence-specific recognition of double helical DNA". He is the recipient of many awards, including the National Medal of Science (2006).
Kim D. Janda is an American chemist who studies on medicinal chemistry, molecular biology, immunology and neuropharmacology.
Nancy Hopkins, an American molecular biologist, is the Amgen, Inc. Professor of Biology at the Massachusetts Institute of Technology. She is a member of the National Academy of Sciences, the Institute of Medicine of the National Academy, and the American Academy of Arts and Sciences. She is known for her research identifying genes required for zebrafish development, and for her earlier research on gene expression in the bacterial virus lambda, and on mouse RNA tumor viruses. She is also known for her work promoting equality of opportunity for women scientists in academia.
Camptothecin (CPT) is a topoisomerase inhibitor. It was discovered in 1966 by M. E. Wall and M. C. Wani in systematic screening of natural products for anticancer drugs. It was isolated from the bark and stem of Camptotheca acuminata, a tree native to China used in traditional Chinese medicine. It has been used clinically in China for the treatment of gastrointestinal tumors. CPT showed anticancer activity in preliminary clinical trials, especially against breast, ovarian, colon, lung, and stomach cancers. However, it has low solubility and adverse effects have been reported when used therapeutically, so synthetic and medicinal chemists have developed numerous syntheses of camptothecin and various derivatives to increase the benefits of the chemical, with good results. Four CPT analogues have been approved and are used in cancer chemotherapy today: topotecan, irinotecan, belotecan, and trastuzumab deruxtecan. Camptothecin has also been found in other plants including Chonemorpha fragrans.
CRLX101 is an experimental approach to cancer chemotherapy that is under investigation in human trials. It is an example of a nanomedicine.
Michael W. Deem is an American engineer, scientist, inventor, and entrepreneur. Deem received his B.S. in chemical engineering from the California Institute of Technology in 1991 and his Ph.D. in chemical engineering from the University of California at Berkeley in 1994. His thesis research was in statistical mechanics and disordered materials with David Chandler. He did postdoctoral research at Harvard University in physics with David R. Nelson. Deem joined the faculty at University of California, Los Angeles, in 1996 and rose to the rank of associate professor of chemical engineering. From 2002 to 2020 Deem was the John W. Cox Professor of Biochemical and Genetic Engineering and professor of physics and astronomy at Rice University in Houston, Texas. Deem was the founding director of the graduate program in systems, synthetic, and physical biology at Rice University, 2012-2014. From 2014 to 2017, Deem served as the chair of the bioengineering department at Rice University.
Stephen James Lippard is the Arthur Amos Noyes Emeritus Professor of Chemistry at the Massachusetts Institute of Technology. He is considered one of the founders of bioinorganic chemistry, studying the interactions of nonliving substances such as metals with biological systems. He is also considered a founder of metalloneurochemistry, the study of metal ions and their effects in the brain and nervous system. He has done pioneering work in understanding protein structure and synthesis, the enzymatic functions of methane monooxygenase (MMO), and the mechanisms of cisplatin anticancer drugs. His work has applications for the treatment of cancer, for bioremediation of the environment, and for the development of synthetic methanol-based fuels.
Thomas C. Bruice was a professor of chemistry and biochemistry at University of California, Santa Barbara. He was elected to the National Academy of Sciences in 1974. He was a pioneering researcher in the area of chemical biology, and is one of the 50 most cited chemists.
Linda Carol Hsieh-Wilson is an American chemist and the Milton and Rosalind Chang Professor of Chemistry at the California Institute of Technology. She is known for her work in chemical neurobiology on understanding the structure and function of carbohydrates in the nervous system. Her studies have revealed critical roles for carbohydrates and protein glycosylation in fundamental processes ranging from cellular metabolism to memory storage. She is a member of the American Academy of Arts and Sciences and was elected to the National Academy of Sciences in 2022.
The duocarmycins are members of a series of related natural products first isolated from Streptomyces bacteria in 1978. They are notable for their extreme cytotoxicity and thus represent a class of exceptionally potent antitumour antibiotics.
Sanjiv Sam Gambhir was an American physician–scientist. He was the Virginia and D.K. Ludwig Professor in Cancer Research, Chairman of the Department of Radiology at Stanford University School of Medicine, and a professor by courtesy in the departments of Bioengineering and Materials Science and Engineering at Stanford University. Additionally, he served as the Director of the Molecular Imaging Program at Stanford (MIPS), Canary Center at Stanford for Cancer Early Detection and the Precision Health and Integrated Diagnostics Center (PHIND). He authored 680 publications and had over 40 patents pending or granted. His work was featured on the cover of over 25 journals including the Nature Series, Science, and Science Translational Medicine. He was on the editorial board of several journals including Nano Letters, Nature Clinical Practice Oncology, and Science Translational Medicine. He was founder/co-founder of several biotechnology companies and also served on the scientific advisory board of multiple companies. He mentored over 150 post-doctoral fellows and graduate students from over a dozen disciplines. He was known for his work in molecular imaging of living subjects and early cancer detection.
Bernard Lucas Feringa is a Dutch synthetic organic chemist, specializing in molecular nanotechnology and homogeneous catalysis. He is the Jacobus van 't Hoff Distinguished Professor of Molecular Sciences, at the Stratingh Institute for Chemistry, University of Groningen, Netherlands, and an Academy Professor of the Royal Netherlands Academy of Arts and Sciences. He was awarded the 2016 Nobel Prize in Chemistry, together with Sir J. Fraser Stoddart and Jean-Pierre Sauvage, "for the design and synthesis of molecular machines".
William Mark Saltzman was named the Goizueta Foundation Professor of Biomedical and Chemical Engineering at Yale University on July 1, 2002 and became the founding chair of Yale's Department of Biomedical Engineering in 2003. Saltzman's research aims to promote new methods for drug delivery and develop new biotechnologies to combat human disease. A pioneer in the fields of biomaterials, nanobiotechnology, and tissue engineering, Saltzman has contributed to the design and implementation of a number of clinical technologies that have become essential to medical practice today. His popular course Frontiers of Biomedical Engineering is available to everyone through Open Yale Courses.
Scott William Lowe is Chair of the Cancer Biology and Genetics Program in the Sloan Kettering Institute at Memorial Sloan Kettering Cancer Center. He is recognized for his research on the tumor suppressor gene, p53, which is mutated in nearly half of cancers.
Michael Tsapatsis is an American chemical engineer and materials scientist. Tsapatsis is the 36th Bloomberg Distinguished Professor at Johns Hopkins University in the Department of Chemical and Biomolecular Engineering. Prior to this position he was the Amundson Chair (2008–present), professor (2003-present), and McKnight Presidential Endowed Chair (2017–present) in the department of chemical engineering and Materials Science at the University of Minnesota. Prior to his appointment at the University of Minnesota, Tsapatsis was an associate professor at the University of Massachusetts Amherst.
Globo H (globohexaosylceramide) is a globo-series glycosphingolipid antigen that is present on the outer membrane of some cancer cells. Globo H is not expressed in normal tissue cells, but is expressed in a number of types of cancers, including cancers of the breast, prostate, and pancreas. Globo H's exclusivity for cancer cells makes it a target of interest for cancer therapies.